抑郁症患者与不明原因胸痛的关联性探讨

目的:分析抑郁症与不明原因胸痛间的关联性及其可能机制,为临床疾病的治疗提供参考依据。方法:纳入2012年6月至2014年5月四川省南充精神卫生中心精神科收治的不明原因胸痛患者35例,作为观察组,另选取35例来院进行常规体检的健康志愿者作为对照组,比较两组的抑郁量表评分、抑郁症发生率、血清C反应蛋白(CRP)、白细胞介素6(IL-6)、五羟色胺(5-HT)及外周血中的CD4+、CD8+含量。结果:与对照组比较,观察组的CRP、IL-6、5-HT、CD4+均低于对照组;且观察组的CD8+、抑郁症发生率(31.43%)、轻中度抑郁及重度抑郁患者比例均高于对照组水平,组间对比差异显著(P<0.05)。结论:抑郁症与不明原因胸痛存在一定相关性,推断可能与CRP、5-HT、IL-6等细胞因子有关,也可能与免疫抑制过程有关,在临床诊治中需引起重视。     

Frustration Intolerance Beliefs: Their Relationship with Depression, Anxiety, and Anger, in a Clinical Population

Beliefs regarding the toleration of frustration and discomfort are often described as underlying psychological disturbance, and represent a fundamental concept in Rational Emotive Behavior Therapy (REBT). Nevertheless, there has been little systematic analysis of the content of these beliefs, which are often treated as a unidimensional construct. This paper investigates the relationship between a multidimensional Frustration Discomfort Scale (FDS) and measures of depressed mood, anxiety, and anger, in a clinical population. Results indicated that FDS sub-scales were differentially related to specific emotions, independent of self-esteem and negative affect. The entitlement sub-scale was uniquely associated with anger, discomfort intolerance with depressed mood, and emotional intolerance with anxiety. These results supported the validity of the FDS, the importance of distinguishing between frustration intolerance dimensions, and of separating these beliefs from those related to self-worth.Copies of the Frustration Discomfort Scale are available from the author on request     

医学生抑郁情绪与家庭及生活事件的相关性研究

目的 探讨医学专业大学生抑郁情绪与家庭及生活事件的相关性，为早期干预提供科学理论依据。方法 采用自拟量表对482名医学专业在校大学生调查，并做影响因素分析。结果 大学生无抑郁或极轻微192人占39．8％；轻度209人占43．4％；中度58人占12％；重度23人占4．8％。生源地、父亲文化程度、专业满意度、人际关系的敏感、学习压力的大小、丧失因子、受惩罚因子和健康适应因子对大学生抑郁情绪的产生有显著影响，而性别、家庭类型和经济情况对医学专业大学生抑郁情绪产生关系不大（P〉0．05）。结论 要重视学生中存在的抑郁情绪问题，采取积极有效措施帮助学生消除抑郁情绪。     

The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9

Human histocompatibility leukocyte antigen E (HLA-E) and mouse major histocompatibility complex (MHC) class Ib antigen, Qa-1, share the same substitutions at two normally conserved positions 143 and 147, which are likely to affect binding of the C terminus of peptides. Qa-1 is able to bind a peptide derived from the leader sequence of H-2 D and H-2 L molecules. We developed a peptide binding assay in vitro to compare the binding specificity of HLA-E with the mouse MHC class Ib molecule Qa-1. We demonstrate that HLA-E binds, although poorly, the peptide which binds to Qa-1 and that it also binds nonamer signal sequence-derived peptides from human MHC class I molecules. Using alanine and glycine substitutions, we could define primary anchor residues at positions 2 and 9 and secondary anchor residues at position 7 and possibly 3.     

TAXUS支架治疗急性冠状动脉综合症的疗效评价

目的评价紫杉醇洗脱冠状动脉支架(TAXUStmBoston公司产品)应用于急性冠状动脉综合症病人的临床疗效及安全性。方法自2003年5月至2004年12月接受TAXUS支架治疗的94例急性冠状动脉综合症患者,观察术后即刻效果、术后6个月心脏性死亡、心肌梗塞、再次血管重建及冠状动脉造影复查情况。病例中包括ST段抬高的急性心肌梗塞27例,非ST段抬高的急性心肌梗死8例,不稳定心绞痛59例。结果支架植入成功率为99%,术中和随访期间无死亡,术后1例出现亚急性血栓,1例晚期血栓致心肌梗塞,另有5例随访中进行了血管重建术,6个月主要心脏不良事件(MACE)发生率7.4%。术后6～7个月23例的冠状动脉造影复查再狭窄率为13.0%(支架内为8.6%),靶病变重建率为2.7%。结论应用TAXUS支架治疗急性冠状动脉综合症是安全和有效的,支架内再狭窄率明显低于普通金属支架。     

心血管疾病并发焦虑抑郁症状2050例心理干预治疗分析

目的:了解心血管疾病并发焦虑抑郁症状的情况并探讨心理干预等对焦虑抑郁症状的影响。方法:对住院的2050例心血管疾病并发焦虑抑郁症状的患者进行回顾性分析。结果:心血管疾病患者中并发有焦虑抑郁症状者占56%;其常表现为类似心绞痛、左心衰竭症状,可并发有心律失常;高血压病并发有焦虑抑郁患者对血压升高的耐受性差,动态血压检查以非勺型改变者居多;单纯使用心血管药物治疗效果欠佳,心理干预,焦虑抑郁症状严重者结合抗焦虑抑郁药物疗效显著。结论:心血管疾病患者常并发焦虑抑郁症状,心理干预治疗等可有效改善患者的症状。     

瑞美隆与氯丙咪嗪治疗抑郁症的对照研究

目的 :探讨瑞美隆与氯丙咪嗪治疗抑郁症患者的疗效与不良反应特点。方法 :随机选取 85例抑郁症患者 ,分别给予瑞美隆与氯丙咪嗪单一治疗 ,并分别于治疗前 ,治疗后第 1、 2、 4、 6周进行汉密尔顿抑郁量表(HAMD) ,临床疗效总评量表 (CGI) ,副反应量表 (TESS)评定。结果 :6周时瑞美隆总显进率为 81 4 % ,明显优于氯丙咪嗪组 (6 1 9% ) (P <0 0 5 ) ;1、 2周时瑞美隆治疗好转率分别为 4 8 8%和 81 4 % ,均分别显著高于同期氯丙咪嗪组 (P <0 0 1和P <0 0 5 ) ,且瑞美隆组HAMD总分第 1周时相对治疗前有显著性差异 (P <0 0 5 )。瑞美隆组TESS分和脱落率显著低于氯丙咪嗪组 ,尤其在口干 ,视物模糊和便秘上均存显著性差异 (P <0 0 1 )。结论 :瑞美隆治疗抑郁症起效快 ,疗效肯定 ,副反应少且轻微 ,依从性好 ,值得在抑郁症患者中广泛应用。     

Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies

Introduction Amisulpride is a substituted benzamide that, at low doses, selectively blocks D2 and D3 presynaptic dopamine receptors, enhancing dopaminergic transmission in frontal cortex and limbic areas. Many clinical studies versus placebo, tricyclic antidepressants and selective serotonin reuptake inhibitors showed amisulpride antidepressant effect, supporting its safety and rapid onset of action. In oncological population, depression is quite frequent and difficult to treat because of the particular sensitivity of cancer patients to the antidepressants’ side effects. Goals of work The aims of this study were to evaluate efficacy, safety and tolerability of low doses of amisulpride (50 mg) in oncological, depressed patients during chemotheraphy. Materials and methods One hundred six consecutive cancer outpatients with depressive symptoms were treated in a prospective, intention to treat, 4-week study, and were evaluated in single-blind with Montgomery Asberg rating scale for depression (MADRS), clinical global impression (CGI) and dosage record treatment emergent symptom scale (DOTES) to assess side effects of treatment. Main results After 4 weeks of treatment, scores of MADRS and CGI significantly improved (p < 0.002; p < 0.001, respectively), with a reduction of depressive symptoms concerning both emotional (such as apparent sadness, reported sadness, inner tension, etc.) and physical cluster (such as lack of appetite, reduction in weight, tiredness and insomnia) with good tolerability (only two patients dropped out). Conclusions This study is the first trial on the use of amisulpride in a cohort of oncological, depressed patients during chemotherapy. Amisulpride demonstrated high efficacy and safety. Controlled studies are needed to confirm these preliminary data.     

精神病人与正常人戒烟前后焦虑抑郁症状的对照研究

目的　了解精神病人和正常人戒烟前后精神状况的变化及差异性 ,探讨戒烟措施。方法　对 71例精神病人和 5 0例正常人戒烟前及戒烟后 1周分别应用汉密顿焦虑量表 (HAMA)、汉密顿抑郁量表 (HAMD)、焦虑自评量表 (SAS)、抑郁自评量表 (SDS)、简明精神病量表 (BPRS )进行测评。结果　精神病人强制性戒烟前HAMA、HAMD、SAS、SDS、BPRS分值分别为 (8.2 1± 6 .4 1)、(7.6 4± 5 .71)、(36 .81± 7.14 )、(33.71± 7.1)、(2 9.4 5± 8.4 7) ;戒烟后HAMA、HAMD、SAS、SDS、BPRS分值分别为 (16 .4 5± 6 .34)、(19.73± 8.71)、(5 8.1± 12 .12 )、(5 6 .31± 11.4 )、(37.32± 7.95 ) ;戒烟前后 5种量表分值变化与正常人戒烟前后分值变化比较有极显著性差异(P <0 .0 1)。结论　对精神病人强制性戒烟可引起明显的情绪反应 ,应适宜控制病人吸烟 ,建立一个合理的管理制度